- Home
- CYH vs ARMP Comparison
CYH vs ARMP Comparison
Compare CYH & ARMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CYH | ARMP |
|---|---|---|
| Founded | 1985 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hospital/Nursing Management | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 432.2M | 383.7M |
| IPO Year | 2000 | 1996 |
Fundamental Metrics
Financial Performance| Metric | CYH | ARMP |
|---|---|---|
| Price | $2.72 | $13.76 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 2 |
| Target Price | $3.45 | ★ $15.00 |
| AVG Volume (30 Days) | ★ 1.1M | 46.6K |
| Earning Date | 04-21-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 196.67 | N/A |
| EPS | ★ 3.77 | N/A |
| Revenue | ★ $12,485,000,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.17 | N/A |
| P/E Ratio | $0.82 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.39 | $1.17 |
| 52 Week High | $4.43 | $14.88 |
Technical Indicators
Market Signals| Indicator | CYH | ARMP |
|---|---|---|
| Relative Strength Index (RSI) | 30.47 | 62.37 |
| Support Level | $2.41 | $5.14 |
| Resistance Level | $2.81 | $13.75 |
| Average True Range (ATR) | 0.12 | 1.33 |
| MACD | -0.01 | 0.27 |
| Stochastic Oscillator | 20.82 | 72.46 |
Price Performance
Historical ComparisonAbout CYH Community Health Systems Inc.
Community Health Systems Inc is a publicly owned hospital operator in the United States. The company also owns four home health agencies and provides management and consulting services to independent hospitals. The firm derives revenue through a broad range of general and specialized hospital healthcare services and outpatient services.
About ARMP Armata Pharmaceuticals Inc.
Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. The company is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck, the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent.